Introducing new capabilities to GPT-Rosalind

OpenAI's GPT-Rosalind launch significantly strengthens AI's role in biotech, offering specialized biological reasoning and drug discovery tools. For the 2026 AI economy, this accelerates pharmaceutical R&D timelines and reduces costs, potentially reshaping the $200B+ life sciences market. It signals a pivot toward vertical AI solutions with tangible commercial impact beyond general-purpose models.